28
Participants
Start Date
August 1, 2025
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2028
Artesunate
Patients with HPV positive CIN2/3 will receive 3 cycles of oral artesunate 200mg OD prior to standard of care therapeutic LLETZ. Each 21 day treatment cycle will comprise oral artesunate 200mg OD for 14 days followed by a 7 day treatment break.
Pusat Perubatan Universiti Malaya, Kuala Lumpur
Institut Kanser Negara, Putrajaya
Hospital Ampang, Ampang
Hospital Selayang, Batu Caves
Hospital Umum Sarawak, Kuching
Lead Sponsor
Collaborators (1)
Clinical Research Malaysia
UNKNOWN
Metanoic Health Ltd.
INDUSTRY